Oaktree Acquisition Corp. III Life Sciences Moves Forward with IPO
Oaktree Acquisition Corp. III Life Sciences (the “Company”) has announced the pricing of its initial public offering (IPO), targeting to raise $175 million through the sale of 17,500,000 units at a price of $10.00 per unit. Each unit will encompass one Class A ordinary share and one-fifth of a redeemable warrant, enabling the company to capitalize on lucrative opportunities within the market.
Market Listing and Trading Symbols
Once the IPO is completed, the units will be traded on The Nasdaq Global Market under the ticker symbol “OACCU.” Expected beginning on October 24, 2024, the shares and warrants will continue to trade under their respective symbols “OACC” and “OACCW.” This strategic step underscores Oaktree's commitment to enhancing its position within the investment landscape.
Strategic Collaboration for Successful IPO
Jefferies, Citigroup Global Markets Inc., and UBS Securities LLC have stepped in as the joint book-running managers for the offering. Oaktree Acquisition Corp. III has granted the underwriters an option to purchase an additional 2,625,000 units to cover any over-allotments, ensuring that they are well-prepared to meet market demand.
Expected Closing and Regulatory Compliance
The offering is projected to close on October 25, 2024, provided it meets the standard closing conditions. The registration statement for the securities was declared effective on October 23, 2024, by the U.S. Securities and Exchange Commission (SEC). This regulatory clearance plays a pivotal role in the company’s ability to move forward confidently.
About Oaktree Acquisition Corp. III Life Sciences
Oaktree Acquisition Corp. III Life Sciences marks the third vehicle formed by Oaktree Capital Management, L.P. to engage in strategic business combinations. This follows the successful mergers between Oaktree Acquisition Corp. and Hims & Hers, as well as Oaktree Acquisition Corp. II with Alvotech. The Company leans on the extensive expertise of Oaktree in the life sciences domain, where it has committed approximately $5 billion across 51 investments since 2013.
Expertise Rooted in Healthcare
With a dedicated team of 12 professionals focusing on life sciences investment, Oaktree Acquisition Corp. III is well-equipped to identify and evaluate noteworthy opportunities within the sector. Their impressive background merges healthcare knowledge with experience in investment banking and operational excellence, which the company believes positions it effectively for future growth.
Overview of Oaktree Capital Management
Oaktree remains a formidable player in the realm of global investment management, specializing in alternative investments and boasting $193 billion in assets under management as of June 30, 2024. The company's investment approach is characterized by its emphasis on value-oriented strategies across various asset classes including credit, private equity, and real estate, striving to cultivate long-term capital appreciation.
Global Impact and Reach
With over 1,200 employees in 23 cities globally, Oaktree's operational scale empowers it to capitalize on diverse investment opportunities. The firm’s commitment to a disciplined approach to investment, alongside a thorough understanding of market dynamics, ensures that it continues to thrive in competitive environments.
Frequently Asked Questions
What is the purpose of Oaktree Acquisition Corp. III Life Sciences?
The Company aims to engage in strategic business combinations with entities in the life sciences sector, leveraging extensive investment expertise.
When did Oaktree Acquisition Corp. III Life Sciences announce its IPO?
The announcement regarding the IPO pricing was made recently, with trading set to commence on October 24, 2024.
Who are the underwriters for this IPO?
Jefferies, Citigroup Global Markets Inc., and UBS Securities LLC are the joint book-running managers overseeing the offering.
What are the expected trading symbols for the securities?
The units will trade under “OACCU,” while the Class A ordinary shares and warrants will be traded under “OACC” and “OACCW,” respectively.
How much capital is Oaktree aiming to raise through this IPO?
The Company is looking to raise $175 million through its initial public offering as it pursues new investment opportunities.
